middle.news
Mesoblast Reports US$30.3M Ryoncil Revenues and Advances Cell Therapy Pipeline
10:40am on Thursday 30th of April, 2026 AEST
•
Healthcare
Read Story
Mesoblast Reports US$30.3M Ryoncil Revenues and Advances Cell Therapy Pipeline
10:40am on Thursday 30th of April, 2026 AEST
Key Points
Ryoncil® net revenues hit US$30.3 million in Q3
Patient recruitment target met in Phase 3 chronic low back pain trial
FDA clears label extension trial for adult SR-aGvHD
Exclusive license acquired for CAR technology to enhance cell therapies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE